Skip to content

Dynamic clinical study of brain imaging and epigenetics in antidepressant treatment of depression

Dynamic clinical study of brain imaging and epigenetics in antidepressant treatment of depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058710
Enrollment
Unknown
Registered
2022-04-14
Start date
2020-11-10
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

Depression:Sertraline tablet or Duloxetine enteric-coated capsules
Normal control group:No

Sponsors

University City Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria of depressive disorder group: 1. Chinese Han patients who meet DSM-5 diagnostic criteria for major depressive disorder; 2. Age 13-55 (including the threshold), gender unlimited, right handedness; 3. Children's Depression Scale (revised version) = 40 points (age<18 years) or Hamilton Depression Scale score = 17 points (age = 18 years) 4. Patients with hypomania symptom checklist (HCL-32) = 13 points to exclude bipolar disorder 5. No psychotropic drugs were used for 3 months before enrollment, and no antidepressant treatment was given for 2 weeks before enrollment; 6. The patient and/or the legal guardian voluntarily participated in the study, understood and signed the written informed consent. Inclusion criteria of healthy control group: 1. No mental illness in the past and at present; 2. 13-55 years old, Han nationality, primary school education or above; 3. The patient and/or the legal guardian voluntarily participated in the study, understood and signed the written informed consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria for depressive disorder group: 1. Patients who previously or currently meet the diagnosis below DSM-5: organic mental disorder, schizophrenia, schizoaffective disorder, bipolar affective disorder, mental retardation, dementia, other cognitive disorders, alcohol and drug dependence, personality disorder, etc; 2. Depression secondary to other mental or physical diseases; 3. Patients with serious or unstable somatic diseases; 4. Patients with epilepsy or other organic brain diseases; 5. Have a history of allergy to antidepressants in the past; 6. Women who are breast-feeding, pregnant or are likely to become pregnant during the trial; Male with fertility requirements within 1 year; 7. At present, there are contraindications to magnetic resonance, such as newly implanted heart stents, metal dentures, etc. Exclusion criteria for healthy control group: 1. Patients with severe or unstable somatic diseases; 2. Past or current organic brain diseases; 3. Two lineages and three generations have a family history of mental illness; 4. Women who are breast-feeding, pregnant or are likely to become pregnant during the trial; Male with fertility requirements within 1 year; 5. At present, there are contraindications to magnetic resonance, such as newly implanted cardiac stents, metal dentures, etc.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale,HAMD;Hamilton Anxiety Scale,HAMA;Depression Scale for Children (Revised);Nine-item Patient Health Questionnaire,PHQ-9;Gene DNA sequences;DNA methylation level;RNA expression level;Brain magnetic resonance;Event-related potential;

Secondary

MeasureTime frame
Udvalg for Kliniske Undersogelser;Gross Rating Scale;Social Work Deficiency Screening Scale;

Countries

China

Contacts

Public ContactKuang Li

University City Hospital of Chongqing Medical University

kuangli0308@163.com+86 13908379733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026